Chinese Expert Consensus on Clinical Application and Management of Recombinant Human Granulocyte-Colony Stimulating Factor (2026 Edition)

Neutropenia is a common hematologic toxicity during antitumor therapy and can induce treatment delays, dose reduction, and even febrile neutropenia (FN), thereby causing poor prognosis. Human granulocyte-colony stimulating factor (G-CSF) has been widely used in the treatment of neutropenia, enabling early disease prevention, reduction in FN incidence, and improvement in antitumor efficacy. However, the standardization of G-CSF in clinical application still needs to be enhanced, and oncology pharmacists play a crucial role in its standardized application. Together with multiple professional committees, the Chinese Anti-Cancer Association Integrated Oncology Pharmacy Committee has developed the consensus to optimize G-CSF application, reduce medical costs, improve G-CSF pharmaceutical monitoring, and enhance patient benefits.